Why the study?
Does recombinant human GH improve bone mineral density in hypopituitary patients with adult-onset GH deficiency?
Population
44 hypopituitary patients with adult-onset GH deficiency (24 men, 20 women; aged 23-66 yr)
Comparison
Recombinant human GH for 2 years vs Baseline (no separate control group)
Design
Cohort, open
Follow-up
2 years
Authors
Loading...
Supports GH for BMD gains in adult GH deficiency; hypothesis-generating without fracture endpoint data from RCTs.
Does recombinant human GH improve bone mineral density in hypopituitary patients with adult-onset GH deficiency?
Two years of GH treatment in adult-onset GH deficiency induces a sustained increase in bone remodeling and a net gain in bone mineral density.
Johannsson et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: